Analyse Liquidia Corporation (LQDA) — Kairos Score 65/100

À propos de Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Informations clés

🕴️ Activité des initiés (90 jours)

46 transactions — 0 achats et 17 ventes déclarés par les dirigeants de Liquidia Corporation.

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur LQDA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur LQDA.

• Stocktwits Wall Street Wrap: Crocs, Liquidia Win Upgrades While SpaceX Competition And Grocery Woes Put AST SpaceMobile, Albertsons Under Pressure
• Why Liquidia (LQDA) Is Up 24.1% After Striking Costly Peace Deal On YUTREPIA Litigation

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.